L&G Global Health & Pharma Index I Acc
Healthcare and BiotechnologyPricing frequency
Daily
Dealing cut off time
13:45
Type
Unit Trust
Yield
1.15%
NAV
158.70p
Income frequency
Annually
Ongoing charge
0.31%
Latest actual NAV date
13-11-2026
ISIN
GB00B0CNH387
UCITS
Yes
Growth of 10k
Asset allocation
Top 10 holdings
| Holdings 30/09/2026 | % of assets |
|---|---|
| Eli Lilly and Co | 11.60 |
| Johnson & Johnson | 7.85 |
| AbbVie Inc | 5.71 |
| Merck & Co Inc | 4.47 |
| UnitedHealth Group Inc | 4.04 |
| Roche Holding AG Ordinary Shares new | 3.67 |
| Novartis AG Registered Shares | 3.30 |
| Thermo Fisher Scientific Inc | 3.08 |
| AstraZeneca PLC | 3.00 |
| Amgen Inc | 2.80 |
Investment objective
The objective of the Fund is to track the performance of the FTSE World Index - Health Care (the “Benchmark Index”) on a net total return basis before fees and expenses are applied. Therefore, the Fund’s performance may differ from the Benchmark Index due to the deduction of fees and expenses and the impact of any tracking error factors. The Benchmark Index is comprised of shares in companies engaged in health, pharmaceuticals and biotechnology. The Fund is a Replicating Fund as it seeks to replicate as closely as possible the constituents of the Benchmark Index by holding all, or substantially all, of the assets comprising the Benchmark Index in similar proportions to their weightings in the Benchmark Index. The Fund will have at least 90% exposure to assets that are included in the Benchmark Index.